ImmuPharma plc (LON:IMM – Get Free Report) shares rose 27% during trading on Friday . The stock traded as high as GBX 3.60 ($0.04) and last traded at GBX 3.60 ($0.04). Approximately 5,919,609 shares traded hands during trading, a decline of 69% from the average daily volume of 18,940,990 shares. The stock had previously closed at GBX 2.84 ($0.04).
ImmuPharma Stock Performance
The firm has a fifty day moving average price of GBX 1.75 and a two-hundred day moving average price of GBX 1.73. The stock has a market capitalization of £16.39 million, a P/E ratio of -393.60 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- Bank Stocks – Best Bank Stocks to Invest In
- Bloom Energy: Powering the Future With Decentralized Energy
- How to Invest in Blue Chip Stocks
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Business Services Stocks Investing
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
